A user's guide for α-synuclein biomarker studies in biological fluids: Perianalytical considerations

Movement Disorders

Volumn 32, Issue 8, 2017, Pages 1117-1130

  Mollenhauer, Brit ^a,b,s   Batrla, Richard ^c,s   El Agnaf, Omar ^d   Galasko, Douglas R ^e   Lashuel, Hilal A ^f,s   Merchant, Kalpana M ^g   Shaw, Lesley M ^h   Selkoe, Dennis J ⁱ   Umek, Robert ^j,s   Vanderstichele, Hugo ^k,s   Zetterberg, Henrik ^l,m,n,s   Zhang, Jing ^o,s   Caspell Garcia, Chelsea ^p   Coffey, Chris ^p   Hutten, Samantha J ^q   Frasier, Mark ^q   Taylor, Peggy ^r,s   Selkoe, Dennis ^s   Du Bowman, Bois ^s   Hyman, Bradley ^s   Juhasz, Peter ^s   Ahlijanian, Michael ^s   Jeromin, Andreas ^s   Parkkinen, Laura ^s   Soto, Claudio ^s   Lee, Steven ^s   Caricasole, Andrea ^s   Petricca, Lara ^s   Paumier, Katrina ^s   Latterich, Martin ^s   Henning Jensen, Poul ^s   Merchant, Kalpana ^s   Hale, John ^s   Giese, Armin ^s   Pochapsky, Thomas ^s   Kotzbauer, Paul ^s   Bartels, Tim ^s   Scherzer, Clemens ^s   Kruse, Niels ^s   Stoops, Erik ^s   Schmid, Adrian ^s   more..

^a Paracelsus Elena Klinik Kassel   (Germany)

^b UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

^c Roche Diagnostics Ltd   (Switzerland)

^d HAMAD BIN KHALIFA UNIVERSITY   (Qatar)

^e UNIVERSITY OF SAN DIEGO   (United States)

^f EPFL   (Switzerland)

^g NORTHWESTERN UNIVERSITY   (United States)

^h UNIVERSITY OF PENNSYLVANIA   (United States)

ⁱ HARVARD MEDICAL SCHOOL   (United States)

^j Meso Scale Discovery   (United States)

^k ADX NEUROSCIENCES   (Belgium)

^l SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^m UNIVERSITY COLLEGE LONDON   (United Kingdom)

ⁿ Dementia Research Institute   (United Kingdom)

^o UNIVERSITY OF WASHINGTON   (United States)

^p UNIVERSITY OF IOWA   (United States)

^q THE MICHAEL J FOX FOUNDATION FOR PARKINSON'S RESEARCH   (United States)

^r BIOLEGEND   (United States)

^s NONE

more..

Author keywords

Biomarker; cerebrospinal fluid; diagnostics; Parkinson's disease; standard operating procedures; synuclein

Indexed keywords

ALPHA SYNUCLEIN; ANTIBODY; BIOLOGICAL MARKER; DETERGENT; DOPAMINE RECEPTOR STIMULATING AGENT; HETEROPHILE ANTIBODY; LEVODOPA;

BLOOD ANALYSIS; BODY FLUID; CENTRIFUGATION; CEREBROSPINAL FLUID; CEREBROSPINAL FLUID ANALYSIS; CIRCADIAN RHYTHM; COMORBIDITY; CONFOUNDING VARIABLE; DIET RESTRICTION; ENZYME LINKED IMMUNOSORBENT ASSAY; FREEZE THAWING; HUMAN; IMMUNOASSAY; LUMBAR PUNCTURE; LUMBAR PUNCTURE NEEDLE; PARKINSON DISEASE; PHENOTYPE; PRIORITY JOURNAL; PROCESSING; PROTEIN BLOOD LEVEL; PROTEIN CEREBROSPINAL FLUID LEVEL; PROTEIN PROCESSING; QUANTITATIVE ANALYSIS; RESEARCH; REVIEW; STANDARDIZATION; STORAGE; METABOLISM;

ALPHA-SYNUCLEIN; BIOMARKERS; HUMANS; PARKINSON DISEASE;

EID: 85028058287     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.27090     Document Type: Review

References (78)

1. Dickson DW, Braak H, Duda JE, et al. Neuropathological assessment of Parkinson's disease: refining the diagnostic criteria. Lancet Neurol 2009;8(12):1150-1157.
2. Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 1992;55(3):181-184.
3. Adler CH, Beach TG, Hentz JG, et al. Low clinical diagnostic accuracy of early vs advanced Parkinson disease: clinicopathologic study. Neurology 2014;83(5):406-412.
4. Fereshtehnejad SM, Romenets SR, Anang JB, Latreille V, Gagnon JF, Postuma RB. New clinical subtypes of Parkinson disease and their longitudinal progression: a prospective cohort comparison with other phenotypes. JAMA Neurol 2015;72(8):863-873.
5. Lawton M, Baig F, Rolinski M, et al. Parkinson's Disease Subtypes in the Oxford Parkinson Disease Centre (OPDC) Discovery Cohort. J Parkinsons Dis 2015;5(2):269-279.
6. Biomarkers Definitions Working G. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther 2001;69(3):89-95.
7. Reiber H. Proteins in cerebrospinal fluid and blood: barriers, CSF flow rate and source-related dynamics. Restor Neurol Neurosci 2003;21(3-4):79-96.
8. Olsson B, Lautner R, Andreasson U, et al. CSF and blood biomarkers for the diagnosis of Alzheimer's disease: a systematic review and meta-analysis. Lancet Neurol 2016;15(7):673-684.
9. Molinuevo JL, Blennow K, Dubois B, et al. The clinical use of cerebrospinal fluid biomarker testing for Alzheimer's disease diagnosis: a consensus paper from the Alzheimer's Biomarkers Standardization Initiative. Alzheimers Dement 2014;10(6):808-817.
10. Vanderstichele H, Bibl M, Engelborghs S, et al. Standardization of preanalytical aspects of cerebrospinal fluid biomarker testing for Alzheimer's disease diagnosis: a consensus paper from the Alzheimer's Biomarkers Standardization Initiative. Alzheimers Dement 2012;8(1):65-73.
11. Cavedo E, Lista S, Khachaturian Z, et al. The road ahead to cure Alzheimer's disease: development of biological markers and neuroimaging methods for prevention trials across all stages and target populations. J Prev Alzheimers Dis 2014;1(3):181-202.
12. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/Regulatory_and_procedural_guideline/2011/02/WC500102018.pdf. Accessed September 14, 2016.
13. Available at: http://www.fda.gov/Drugs/DevelopmentApprovalProcess/ucm434382.htm. Accessed September 14, 2016.
14. Spillantini MG, Schmidt ML, Lee VM, Trojanowski JQ, Jakes R, Goedert M. Alpha-synuclein in Lewy bodies. Nature 1997;388(6645):839-840.
15. Singleton AB, Farrer M, Johnson J, et al. alpha-Synuclein locus triplication causes Parkinson's disease. Science 2003;302(5646):841.
16. Chartier-Harlin M-C, Kachergus J, Roumier C, et al. Alpha-synuclein locus duplication as a cause of familial Parkinson's disease. Lancet 2004;364(9440):1167-1169.
17. Simonsen AH, Kuiperij B, El-Agnaf OM, et al. The utility of alpha-synuclein as biofluid marker in neurodegenerative diseases: a systematic review of the literature. Biomark Med 2016;10(1):19-34.
18. Hong Z, Shi M, Chung KA, et al. DJ-1 and alpha-synuclein in human cerebrospinal fluid as biomarkers of Parkinson's disease. Brain 2010;133(Pt 3):713-726.
19. Mollenhauer B, Locascio JJ, Schulz-Schaeffer W, Sixel-Doring F, Trenkwalder C, Schlossmacher MG. alpha-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study. Lancet Neurol 2011;10(3):230-240.
20. El-Agnaf OM, Salem SA, Paleologou KE, et al. Alpha-synuclein implicated in Parkinson's disease is present in extracellular biological fluids, including human plasma. FASEB J 2003;17(13):1945-1947.
21. Tokuda T, Salem SA, Allsop D, et al. Decreased alpha-synuclein in cerebrospinal fluid of aged individuals and subjects with Parkinson's disease. Biochem Biophys Res Commun 2006;349(1):162-166.
22. Schmid AW, Fauvet B, Moniatte M, Lashuel HA. Alpha-synuclein post-translational modifications as potential biomarkers for Parkinson's disease and other synucleinopathies. Mol Cell Proteomics 2013;12(12):2543-2558.
23. El-Agnaf OM, Salem SA, Paleologou KE, et al. Detection of oligomeric forms of alpha-synuclein protein in human plasma as a potential biomarker for Parkinson's disease. FASEB J 2006;20(3):419-425.
24. Lleo, A, Cavedo E, Parnetti L, et al. Cerebrospinal fluid biomarkers in trials for Alzheimer and Parkinson diseases. Nat Rev Neurol 2015;11(1):41-55.
25. Kang JH, Irwin DJ, Chen-Plotkin AS, et al. Association of cerebrospinal fluid beta-amyloid 1-42, T-tau, P-tau181, and alpha-synuclein levels with clinical features of drug-naive patients with early Parkinson disease. JAMA Neurol 2013;70(10):1277-1287.
26. Magdalinou NK, Paterson RW, Schott JM, et al. A panel of nine cerebrospinal fluid biomarkers may identify patients with atypical parkinsonian syndromes. J Neurol Neurosurg Psychiatry 2015;86(11):1240-1247.
27. Hall S, Ohrfelt A, Constantinescu R, et al. Accuracy of a panel of 5 cerebrospinal fluid biomarkers in the differential diagnosis of patients with dementia and/or parkinsonian disorders. Arch Neurol 2012;6(11):1445-1552.
28. Mollenhauer B, Trautmann E, Otte B, et al. alpha-Synuclein in human cerebrospinal fluid is principally derived from neurons of the central nervous system. J Neural Transm 2012;119(7):739-746.
29. Sui YT, Bullock KM, Erickson MA, Zhang J, Banks WA. Alpha synuclein is transported into and out of the brain by the blood-brain barrier. Peptides 2014;62:197-202.
30. Braak H, Del Tredici K, Rub U, de Vos RA, Jansen Steur EN, Braak E. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging 2003;24(2):197-211.
31. Del Tredici K, Hawkes CH, Ghebremedhin E, Braak H. Lewy pathology in the submandibular gland of individuals with incidental Lewy body disease and sporadic Parkinson's disease. Acta Neuropathol 2010;119(6):703-713.
32. Adler CH, Dugger BN, Hinni ML, et al. Submandibular gland needle biopsy for the diagnosis of Parkinson disease. Neurology 2014;82(10):858-864.
33. Devic I, Hwang H, Edgar JS, et al. Salivary & alpha;-synuclein and DJ-1: potential biomarkers for Parkinson's disease. Brain 2011;134(Pt 7):e178.
34. Shi M, Sui YT, Peskind ER, et al. Salivary tau species are potential biomarkers of Alzheimer's disease. J Alzheimers Dis 2011;27(2):299-305.
35. Devic I, Hwang H, Edgar JS, et al. Salivary alpha-synuclein and DJ-1: potential biomarkers for Parkinson's disease. Brain 2011;134(Pt 7):e178.
36. Barbour R, Kling K, Anderson JP, et al. Red blood cells are the major source of alpha-synuclein in blood. Neurodegener Dis 2008;5(2):55-59.
37. Duran R, Barrero FJ, Morales B, Luna JD, Ramirez M, Vives F. Plasma alpha-synuclein in patients with Parkinson's disease with and without treatment. Mov Disord 2010;25(4):489-493.
38. Fjorback AW, Varming K, Jensen PH. Determination of alpha-synuclein concentration in human plasma using ELISA. Scand J Clin Lab Invest 2007;67(4):431-435.
39. Lee PH, Lee G, Park HJ, Bang OY, Joo IS, Huh K. The plasma alpha-synuclein levels in patients with Parkinson's disease and multiple system atrophy. J Neural Transm 2006;113(10):1435-1439.
40. Li QX, Mok SS, Laughton KM, et al. Plasma alpha-synuclein is decreased in subjects with Parkinson's disease. Exp Neurol 2007;204(2):583-588.
41. Kang JH, Mollenhauer B, Coffey CS, et al. CSF biomarkers associated with disease heterogeneity in early Parkinson's disease: the Parkinson's Progression Markers Initiative study. Acta Neuropathol 2016;131(6):935-949.
42. Trojanowski JQ, Vandeerstichele H, Korecka M, et al. Update on the biomarker core of the Alzheimer's Disease Neuroimaging Initiative subjects. Alzheimers Dement 2010;6(3):230-238.
43. Parnetti L, Cicognola C, Eusebi P, Chiasserini D. Value of cerebrospinal fluid alpha-synuclein species as biomarker in Parkinson's diagnosis and prognosis. Biomark Med 2016;10(1):35-49.
44. del Campo M, Mollenhauer B, Bertolotto A, et al. Recommendations to standardize preanalytical confounding factors in Alzheimer's and Parkinson's disease cerebrospinal fluid biomarkers: an update. Biomark Med 2012;6(4):419-430.
45. Sako W, Murakami N, Izumi Y, Kaji R. Reduced alpha-synuclein in cerebrospinal fluid in synucleinopathies: evidence from a meta-analysis. Mov Disord 2014;29(13):1599-1605.
46. Eusebi P, Giannandrea D, Biscetti L, et al. Diagnostic utility of CSF alpha-synuclein species in Parkinson's disease: protocol for a systematic review and meta-analysis. BMJ Open 2016;6(6):e011113.
47. Mollenhauer B, Parnetti L, Rektorova I, et al. Biological confounders for the values of cerebrospinal fluid proteins in Parkinson's disease and related disorders. J Neurochem 2016;139(Suppl 1):290-317.
48. Mignini F, Bronzetti E, Felici L, et al. Dopamine receptor immunohistochemistry in the rat choroid plexus. J Auton Pharmacol 2000;20(5-6):325-332.
49. Mollenhauer B, Caspell-Garcia CJ, Coffey CS, et al. Longitudinal cerebrospinal fluid biomarkers in early Parkinson's disease and healthy controls. Neurology 2017, submitted.
50. Xie L, Kang H, Xu Q, et al. Sleep drives metabolite clearance from the adult brain. Science 2013;342(6156):373-377.
51. Murillo-Rodriguez E, Desarnaud F, Prospero-Garcia O. Diurnal variation of arachidonoylethanolamine, palmitoylethanolamide and oleoylethanolamide in the brain of the rat. Life Sci 2006;79(1):30-37.
52. Bateman RJ, Wen G, Morris JC, Holtzman DM. Fluctuations of CSF amyloid-beta levels: implications for a diagnostic and therapeutic biomarker. Neurology 2007;68(9):666-669.
53. Zetterberg H, Tullhog K, Hansson O, Minthon L, Londos E, Blennow K. Low incidence of post-lumbar puncture headache in 1,089 consecutive memory clinic patients. Eur Neurol 2010;63(6):326-330.
54. Kuntz KM, Kokmen E, Stevens JC, Miller P, Offord KP, Ho MM. Post-lumbar puncture headaches: experience in 501 consecutive procedures. Neurology 1992;42(10):1884-1887.
55. Vanderstichele HM, Janelidze S, Demeyer L, et al. Optimized Standard Operating Procedures for the Analysis of Cerebrospinal Fluid Abeta42 and the Ratios of Abeta Isoforms Using Low Protein Binding Tubes. J Alzheimers Dis 2016;53(3):1121-1132.
56. Perret-Liaudet A, Pelpel M, Tholance Y, et al. Risk of Alzheimer's disease biological misdiagnosis linked to cerebrospinal collection tubes. J Alzheimers Dis 2012;31(1):13-20.
57. Lehmann S, Schraen S, Quadrio I, et al. Impact of harmonization of collection tubes on Alzheimer's disease diagnosis. Alzheimers Dement 2014;10(5 Suppl):S390-S4 e2.
58. Lewczuk P, Beck G, Esselmann H, et al. Effect of sample collection tubes on cerebrospinal fluid concentrations of tau proteins and amyloid beta peptides. Clin Chem 2006;52(2):332-334.
59. Pica-Mendez AM, Tanen M, Dallob A, Tanaka W, Laterza OF. Nonspecific binding of Abeta42 to polypropylene tubes and the effect of Tween-20. Clin Chim Acta 2010;411(21-22):1833.
60. Sahai S, Arora RC, Meltzer HY. Platelet monoamine oxidase. I: Effect of temperature, anticoagulant, and centrifugation technique. Biol Psychiatry 1981;16(11):1077-1083.
61. Compta Y, Valente T, Saura J, et al. Correlates of cerebrospinal fluid levels of oligomeric- and total-alpha-synuclein in premotor, motor and dementia stages of Parkinson's disease. J Neurol 2015;262(2):294-306.
62. Llorens F, Schmitz M, Varges D, et al. Cerebrospinal alpha-synuclein in alpha-synuclein aggregation disorders: tau/alpha-synuclein ratio as potential biomarker for dementia with Lewy bodies. J Neurol 2016;263(11):2271-2277.
63. Jimenez CR, Koel-Simmelink M, Pham TV, van der Voort L, Teunissen CE. Endogeneous peptide profiling of cerebrospinal fluid by MALDI-TOF mass spectrometry: optimization of magnetic bead-based peptide capture and analysis of preanalytical variables. Proteomics Clin Appl 2007;1(11):1385-1392.
64. West-Nielsen M, Hogdall EV, Marchiori E, Hogdall CK, Schou C, Heegaard NH. Sample handling for mass spectrometric proteomic investigations of human sera. Anal Chem 2005;77(16):5114-5123.
65. Rosenling T, Slim CL, Christin C, et al. The effect of preanalytical factors on stability of the proteome and selected metabolites in cerebrospinal fluid (CSF). J Proteome Res 2009;8(12):5511-5522.
66. Bhatnagar BS, Bogner RH, Pikal MJ. Protein stability during freezing: separation of stresses and mechanisms of protein stabilization. Pharm Devel Technol 2007;12(5):505-523.
67. Murphy BM, Swarts S, Mueller BM, van der Geer P, Manning MC, Fitchmun MI. Protein instability following transport or storage on dry ice. Nat Meth 2013;10(4):278-279.
68. Le Bastard N, De Deyn PP, Engelborghs S. Importance and impact of preanalytical variables on Alzheimer disease biomarker concentrations in cerebrospinal fluid. Clin Chem 2015;61(5):734-743.
69. Ishii R, Tokuda T, Tatebe H, et al. Decrease in plasma levels of alpha-synuclein is evident in patients with Parkinson's disease after elimination of heterophilic antibody interference. PLoS One 2015;10(4):e0123162.
70. Mollenhauer B, Cullen V, Kahn I, et al. Direct quantification of CSF alpha-synuclein by ELISA and first cross-sectional study in patients with neurodegeneration. Exp Neurol 2008;213(2):315-325.
71. Valentin MA, Ma S, Zhao A, Legay F, Avrameas A. Validation of immunoassay for protein biomarkers: bioanalytical study plan implementation to support pre-clinical and clinical studies. J Pharm Biomed Anal 2011;55(5):869-877.
72. Bjerke M, Andreasson U, Kuhlmann J, et al. Assessing the commutability of reference material formats for the harmonization of amyloid-beta measurements. Clin Chem Lab Med 2016;54(7):1177-1191.
73. Vanderstichele H, De Meyer G, Shapiro F, et al. Alzheimer's Disease Biomarkers: From Concept to Clinical Utility. Nova Science Publishers, Inc.; 2008.
74. Gottschalk PG, Dunn JR. The five-parameter logistic: a characterization and comparison with the four-parameter logistic. Anal Biochem 2005;343(1):54-65.
75. Schmid AW, Fauvet B, Moniatte M, Lashuel HA. Alpha-synuclein post-translational modifications as potential biomarkers for Parkinson disease and other synucleinopathies. Mol Cell Proteomics 2013;12(12):3543-3558.
76. Tomlinson CL, Stowe R, Patel S, Rick C, Gray R, Clarke CE. Systematic review of levodopa dose equivalency reporting in Parkinson's disease. Mov Disord 2010;25(15):2649-2653.
77. Wright BL, Lai JT, Sinclair AJ. Cerebrospinal fluid and lumbar puncture: a practical review. J Neurol 2012;259(8):1530-1545.
78. You JS, Gelfanova V, Knierman MD, Witzmann FA, Wang M, Hale JE. The impact of blood contamination on the proteome of cerebrospinal fluid. Proteomics 2005;5(1):290-296.